RecruitingNot Applicable

Efficacy and Safety of Surgical Treatment for Type IVa CBD

China1,500 participantsStarted 2025-07-14

Plain-language summary

This study is a multicenter, bidirectional cohort study aimed at continuously enrolling patients with biliary dilatation from 25 medical centers in China. It will collect comprehensive life-cycle data from the cohort to establish a Chinese cohort for IVa biliary dilatation (BD). Based on this cohort, the study seeks to compare the perioperative risks, long-term outcomes, and quality of life of type IVa BD following surgical treatment, to establish standardized surgical treatment strategies for type IVa BD.

Who can participate

Age range80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients who have been diagnosed with Todani type IVa BD.
✓. Patients aged between 0 and 80 years old, regardless of gender.
✓. First-time receipt of surgery.

Exclusion criteria

✕. With abnormal intrapancreatic bile duct
✕. Inappropriate Roux-loop length (outside the range of 40-60 cm for adults and 15-30 cm for children)
✕. With non-relevant surgical interventions
✕. Pathologically confirmed carcinogenesis
✕. Unresolved choledocholithiasis, bile duct stenosis, and Intrahepatic bile duct stones during the procedure.
✕. Unavailable follow-up information.

What they're measuring

Long-term complication-free survival (LCFS)

Timeframe: After 30 or 90 days of surgery

Trial details

NCT IDNCT07036848

SponsorBeijing Tsinghua Chang Gung Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07-14

Contact for this trial

Changzhen Yang, MD

+86 18810915262 ycz23@mail.tsinghua.edu.cn

View on ClinicalTrials.gov More Choledochal Cyst trials